PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DR26F1HE44571744359!dupixent 300 MG 2 ML PEN 2ml — Amerisourcebergen Drug Corp

Amerisourcebergen Drug Corp holds $19.3B across 1,357,999 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2DR25D1205. PoP ended May 7, 2026 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support
Awarding office
Amerisourcebergen Drug Corp
Recipient
May 7, 2026
PoP end
$140K
Obligated
$140K
Potential
424210
NAICS
6505
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Amerisourcebergen Drug Corp — $90

Contract facts

Federal
Contract numberSPE2DR26F1HE4
Also listed asSPE2DR25D1205-SPE2DR26F1HE4
AgencyDla Troop Support
Awarding officeDla Troop Support
Awarding agencyDepartment of Defense (DOD)
Funding agencyDepartment of Defense (DOD)
IncumbentAmerisourcebergen Drug Corp
CAGE1XUY5
UEIKABZK8W6PQT3
NAICS424210

No full NAICS 424210 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDVSPE2DR25D1205
Place of performanceCONSHOHOCKEN PA
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startMay 6, 2026
PoP end (current)May 7, 2026
Obligated$140K
Current value$140K
Potential value$140K

4571744359!DUPIXENT 300 MG/2 ML PEN 2ML is a federal award for Dla Troop Support held by Amerisourcebergen Drug Corp. Estimated value $140K ($140K obligated). Current period of performance ends May 7, 2026. Place of performance: CONSHOHOCKEN PA.

Recompete timing

Public
Past PoP end (106 days ago)

Current PoP ended May 7, 2026 (106 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Amerisourcebergen Drug Corp$19.3B obligated across 1,357,999 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($19.3B) · all agencies
Department of Defense (DOD)$19.3B · 100%Department of Health and Human Services (HHS)$7.6M · 0%Department of Veterans Affairs (VA)$5.9M · 0%Department of Justice (DOJ)$68K · 0%
Open full company profile

Related awards

Same parent · incumbent
36C77026P0121
DROSPIRENONE
$321K
Sep 27, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract SPE2DR26F1HE4?

SPE2DR26F1HE4 (4571744359!dupixent 300 MG 2 ML PEN 2ml) is a Dla Troop Support award with a potential value of $140K, currently held by Amerisourcebergen Drug Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2DR26F1HE4?

Dla Troop Support awarded SPE2DR26F1HE4 to Amerisourcebergen Drug Corp (potential $140K).

Who is the incumbent on SPE2DR26F1HE4?

Amerisourcebergen Drug Corp is the incumbent with $19.3B across 1357999 related awards in SCOUT’s public footprint. The current period of performance ends May 7, 2026.

When does Amerisourcebergen Drug Corp’s SPE2DR26F1HE4 come up for recompete?

SCOUT tracks a period-of-performance end of May 7, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/SPE2DR26F1HE4